Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cirhin mRNA is the transcript of the CIRH1A gene (also known as UTP4), which encodes the Cirhin protein, a critical component of the small subunit (SSU) processome [UniProt: P58557]. This complex is essential for the endonucleolytic cleavage and processing of pre-ribosomal RNA, specifically the maturation of 18S rRNA required for the assembly of the 40S ribosomal subunit [PubMed: 15805465]. Mutations in the CIRH1A mRNA, most notably the c.1693C>T (p.Arg565Trp) missense mutation, are the primary cause of North American Indian Childhood Cirrhosis (NAIC), a severe autosomal recessive intrahepatic cholestasis found in the Ojibway-Cree population [PubMed: 12145751]. While there are currently no approved pharmacological agents targeting this molecule, CIRH1A mRNA is a candidate for potential gene therapy or RNA-based interventions aimed at correcting the underlying genetic defect [OMIM: 607456]. Because Cirhin is vital for global protein synthesis machinery, therapeutic strategies must be highly specific to avoid broad cytotoxic effects resulting from ribosome deficiency [PubMed: 21135508].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cirhin mRNA (CIRH1A mRNA).